

Notification Date: June 4, 2024 Effective Date: July 10, 2024

MLH1 Hypermethylation Analysis, Tumor

Test ID: ML1HM

Explanation:

On the effective date, the Ordering Guidance and Necessary Information will update, as shown below.

Current Ordering Guidance

This test is **not** recommended as a first-tier screening measure for hereditary nonpolyposis colon cancer. For more information see TMSI / Microsatellite Instability, Tumor and IHC / Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor.

Testing will only be performed on colon or endometrial tumors demonstrating loss of *MLH1* protein expression by immunohistochemistry.

Mayo Clinic's preferred screening test includes both *MLH1* promoter hypermethylation and *BRAF* V600E testing. Order BRMLH / *MLH1* Hypermethylation and *BRAF* Mutation Analysis, Tumor.

Extracted DNA from tissues is **not** an acceptable specimen type.

New Ordering Guidance

This test is **not** recommended as a first-tier screening measure for hereditary nonpolyposis colon cancer. For more information see TMSI / Microsatellite Instability, Tumor and IHC / Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor.

Testing will only be performed on colon or endometrial tumors demonstrating loss of *MLH1* protein expression by immunohistochemistry.

Mayo Clinic's preferred screening test includes both *MLH1* promoter hypermethylation and *BRAF* V600E testing. Order BRMLH / *MLH1* Hypermethylation and *BRAF* Mutation Analysis, Tumor.

Extracted DNA from tissues is **not** an acceptable specimen type.

If the MMR IHC results for MLH1 and/or PMS2 suggest possible tumor heterogeneity, are ambiguous or unusual, please also send the physical IHC stains as they will be needed to optimize the area of tissue selected for testing and for interpretation of the results. If IHCs are not sent upfront and the available results meeting any of the listed criteria (suggest possible tumor heterogeneity, are ambiguous or unusual) we will remedy to request the stains in order to test which will result in a slight delay of testing.

Current Necessary Information

Pathology report **must** accompany specimen in order for testing to be performed.

New Necessary Information

Pathology report and MMR IHC results must accompany specimen in order for testing to be performed.

Questions

Contact Michelle Raths, Laboratory Resource Coordinator at 800-533-1710.